Successful theranostics have been developed for somatostatin receptor positive neuroendocrine tumors with [68Ga/177Lu]DOTATATE and prostate-specific membrane antigen (PSMA) positive prostate cancer patients as prime examples (10–13). This evidence concerns the gene FOLH1 and prostate carcinoma.